526 related articles for article (PubMed ID: 12641624)
1. Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study.
Koh JM; Kim ES; Ryu JS; Hong SJ; Kim WB; Shong YK
Clin Endocrinol (Oxf); 2003 Apr; 58(4):421-7. PubMed ID: 12641624
[TBL] [Abstract][Full Text] [Related]
2. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
[TBL] [Abstract][Full Text] [Related]
3. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
[TBL] [Abstract][Full Text] [Related]
5. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
[TBL] [Abstract][Full Text] [Related]
6. Timing of post 131I ablation diagnostic whole body scan in differentiated thyroid cancer patients. Less than four months post ablation may be too early.
Winter M; Winter J; Heinzel A; Behrendt FF; Krohn T; Mottaghy FM; Verburg FA
Nuklearmedizin; 2015; 54(4):151-7. PubMed ID: 26028188
[TBL] [Abstract][Full Text] [Related]
7. The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning.
Siddiqi A; Foley RR; Britton KE; Sibtain A; Plowman PN; Grossman AB; Monson JP; Besser GM
Clin Endocrinol (Oxf); 2001 Oct; 55(4):515-21. PubMed ID: 11678835
[TBL] [Abstract][Full Text] [Related]
8. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
[TBL] [Abstract][Full Text] [Related]
9. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan.
Pineda JD; Lee T; Ain K; Reynolds JC; Robbins J
J Clin Endocrinol Metab; 1995 May; 80(5):1488-92. PubMed ID: 7744991
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of observation without repeated radioiodine therapy in differentiated thyroid carcinoma patients with positive surveillance whole-body scans and negative thyroglobulin.
Lim DJ; O JH; Kim MH; Kim JH; Kwon HS; Kim SH; Kang MI; Cha BY; Lee KW; Son HY
Korean J Intern Med; 2010 Dec; 25(4):408-14. PubMed ID: 21179279
[TBL] [Abstract][Full Text] [Related]
11. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.
Alzahrani AS; Mohamed G; Al Shammary A; Aldasouqi S; Abdal Salam S; Shoukri M
J Endocrinol Invest; 2005 Jun; 28(6):540-6. PubMed ID: 16117196
[TBL] [Abstract][Full Text] [Related]
12. Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan.
Chao M
Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):438-47. PubMed ID: 20561773
[TBL] [Abstract][Full Text] [Related]
13. The predictive value of serum thyroglobulin in the follow-up of differentiated thyroid cancer.
Roelants V; Nayer PD; Bouckaert A; Beckers C
Eur J Nucl Med; 1997 Jul; 24(7):722-7. PubMed ID: 9211756
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of radioiodine therapy in differentiated thyroid cancer subjects with elevated serum thyroglobulin and negative whole body scan using 131I with emphasize on the thallium scintigraphy in these subgroups.
Zakani A; Saghari M; Eftekhari M; Fard-Esfahani A; Fallahi B; Esmaili J; Assadi M
Eur Rev Med Pharmacol Sci; 2011 Oct; 15(10):1215-21. PubMed ID: 22165686
[TBL] [Abstract][Full Text] [Related]
15. Lithium as an adjuvant in the postoperative ablation of remnant tissue in low-risk thyroid carcinoma.
Yamazaki CA; Padovani RP; Biscolla RP; Ikejiri ES; Marchetti RR; Castiglioni ML; Matsumura LK; Maciel RM; Furlanetto RP
Thyroid; 2012 Oct; 22(10):1002-6. PubMed ID: 22953991
[TBL] [Abstract][Full Text] [Related]
16. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?
Salvatori M; Perotti G; Rufini V; Maussier ML; Dottorini M
Clin Endocrinol (Oxf); 2004 Dec; 61(6):704-10. PubMed ID: 15579184
[TBL] [Abstract][Full Text] [Related]
17. Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal.
Oyen WJ; Verhagen C; Saris E; van den Broek WJ; Pieters GF; Corsten FH
J Nucl Med; 2000 Apr; 41(4):643-6. PubMed ID: 10768565
[TBL] [Abstract][Full Text] [Related]
18. Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow up of differentiated thyroid carcinoma.
Brendel AJ; Lambert B; Guyot M; Jeandot R; Dubourg H; Roger P; Wynchauk S; Manciet G; Lefort G
Eur J Nucl Med; 1990; 16(1):35-8. PubMed ID: 2307172
[TBL] [Abstract][Full Text] [Related]
19. Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results?
Ma C; Xie J; Kuang A
J Nucl Med; 2005 Jul; 46(7):1164-70. PubMed ID: 16000286
[TBL] [Abstract][Full Text] [Related]
20. Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scan.
Kim WG; Ryu JS; Kim EY; Lee JH; Baek JH; Yoon JH; Hong SJ; Kim ES; Kim TY; Kim WB; Shong YK
J Clin Endocrinol Metab; 2010 Mar; 95(3):1169-73. PubMed ID: 20080852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]